Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial - The Lancet Oncology
Evolving Immuno-Chemotherapeutic Paradigms in Esophageal and Gastric Cancers | Published in healthbook TIMES Oncology Hematology
Efficacy of Combination Chemotherapy Using a Novel Oral Chemotherapeutic Agent, TAS-102, with Oxaliplatin on Human Colorectal and Gastric Cancer Xenografts | Anticancer Research
Late-line treatment in metastatic gastric cancer: today and tomorrow | Semantic Scholar
Relative tumor volume (RTV) (a) and body weight change (BWC) (b) in... | Download Scientific Diagram
Korean Practice Guideline for Gastric Cancer 2018: an Evidence-based, Multi-disciplinary Approach
Efficacy of trifluridine and tipiracil (TAS-102) versus placebo, with supportive care, in a randomized, controlled trial of patients with metastatic colorectal cancer from Spain: results of a subgroup analysis of the phase
Cancers | Free Full-Text | Recent Trends and Advancements in the Diagnosis and Management of Gastric Cancer
Efficacy and safety of trifluridine/tipiracil plus ramucirumab in comparison with trifluridine/tipiracil monotherapy for patients with advanced gastric cancer–single institutional experience | Gastric Cancer
Progress and challenges in HER2-positive gastroesophageal adenocarcinoma | Journal of Hematology & Oncology | Full Text
Frontiers | Comparison of Efficacy and Safety of Third-Line Treatments for Advanced Gastric Cancer: A Systematic Review With Bayesian Network Meta-Analysis
Novel oral chemotherapeutic holds potential for stomach cancer patients
Dihydroartemisinin suppresses proliferation, migration, the Wnt/β‑catenin pathway and EMT via TNKS in gastric cancer Corrigendum in /10.3892/ol.2021.13152
Efficacy of Combination Chemotherapy Using a Novel Oral Chemotherapeutic Agent, TAS-102, with Irinotecan Hydrochloride on Human Colorectal and Gastric Cancer Xenografts | Anticancer Research
Department of Gastrointestinal Oncology
Ramucirumab beyond progression plus TAS‐102 in patients with advanced or metastatic esophagogastric adenocarcinoma, after treatment failure on a ramucirumab‐based therapy - Goetze - 2023 - International Journal of Cancer - Wiley Online Library
LONSURF® (trifluridine and tipiracil) tablets Efficacy | Previously Treated Metastatic GEJ and Gastric Cancer Treatment
TAGS: A Phase 3, Randomised, Double-blind Study of Trifluridine/Tipiracil ( TAS-102) Versus Placebo in Patients With Refractory Metastatic Gastric Cancer. - ppt download
LONSURF® (trifluridine and tipiracil) tablets Efficacy | Previously Treated Metastatic GEJ and Gastric Cancer Treatment
Trifluridine/Tipiracil: A Review in Metastatic Gastric Cancer - YouTube
LONSURF® (trifluridine and tipiracil) tablets Efficacy | Previously Treated Metastatic GEJ and Gastric Cancer Treatment
New developments and standard of care in the management of advanced gastric cancer - ScienceDirect
OncLive - The Japanese Ministry of Health, Labour and Welfare has approved TAS-102 (trifluridine/tipiracil; Lonsurf) for the treatment of patients with unresectable advanced or recurrent gastric cancer that has progressed after chemotherapy.
Gastric Cancer Foundation lonsurf Archives | Gastric Cancer Foundation
Scenario 1. FLOT, TAS-102, IOs Do They Improve the Lives of Patients With Gastric Cancer? - ppt download
Gastric cancer: Translating novels concepts into clinical practice - ScienceDirect
LONSURF® (trifluridine and tipiracil) tablets Efficacy | Previously Treated Metastatic GEJ and Gastric Cancer Treatment
Targeted and novel therapy in advanced gastric cancer | Experimental Hematology & Oncology | Full Text
